Skip to content

Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing

A Randomized Controlled Trial of NMES vs. Traditional Dysphagia Therapy After Stroke

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01279824
Acronym
ANSRS
Enrollment
53
Registered
2011-01-19
Start date
2008-04-30
Completion date
2011-04-30
Last updated
2012-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia

Keywords

swallowing, treatment, stroke,rehabilitation

Brief summary

Neuromuscular Electrical stimulation (NMES) for swallowing has recently been proposed for the treatment of dysphagia post stroke and is clinically receiving favor as a treatment modality, in the absence of strong research support. This study aims to investigate the effect of NMES therapy for dysphagia upon recovery of swallowing function following stroke. The study will follow a pilot randomized controlled trial design. Fifty one patients admitted to a sub-acute rehabilitation facility will be clinically screened for dysphagia, and randomized into one of three groups, NMES, sham NMES or usual care -behavioral swallowing therapy arm. All patients will be treated for one hour per day for 3 weeks, and their progress and outcome will be monitored. The results will add to the preliminary data on the effectiveness of this form of swallowing treatment for patients following stroke, and has the potential to enable more efficient allocation of resources to post-acute rehabilitation and thus benefit afforded to stroke patients, and the community.

Detailed description

This pilot randomized controlled trial (N=51) includes stroke patients admitted to a sub-acute rehabilitation facility. Subjects will be clinically screened for dysphagia, and randomized into three groups, NMES, sham NMES or usual care -behavioral swallowing therapy arm. Following randomization, all subjects will undergo a video-x-ray (modified barium swallow) of swallowing to confirm the presence of oropharyngeal dysphagia and provide objective data about the nature and degree of dysphagia. All patients will be treated for one hour per day for 3 weeks, and their progress and outcome will be recorded. Participants will be independently evaluated by a blinded assessor at baseline, post treatment and at 3 months following treatment. The primary outcome will be improvement in clinical swallowing ability, oral intake level, and body weight. The results will add to the preliminary data on the effectiveness of this form of swallowing treatment for patients following stroke.

Interventions

Standardized behavioral swallowing intervention

Sponsors

National Center for Medical Rehabilitation Research (NCMRR)
CollaboratorNIH
University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Stroke identified by neurological and radiological examination * Oropharyngeal dysphagia as confirmed by clinical and radiological examination * No prior history of oropharyngeal dysphagia by patient and/or caregiver report * No previous head/neck surgery or trauma that may impact swallowing ability * No other/concomitant neurological disorders (e.g. Parkinson's disease) that would impact oropharyngeal swallowing ability. This does not include post-stroke deficits. * Physician and patient/family agreement to participate.

Exclusion criteria

* Exposed to previous behavioral or NMES swallowing therapy within 6 months of admission * Presence of progressive neurological disorder, such as ALS; Parkinson's or other neurologic disorders within the last 6 months; * History of neurosurgery (either ablative or stimulatory), encephalitis or significant head trauma. * History of a significant medical condition such as heart, liver, or renal disease; history or evidence of malignancy within the past 5 years other than excised basal cell carcinoma. * Because of FDA Warnings, patients with cardiac demand pace makers will be excluded. * Patients with evidence of significant cognitive impairment or dementia as reflected in a Mini-Mental test less than 23 and/or a score of 50% or less on the comprehension quotient on the Western Aphasia Battery.

Design outcomes

Primary

MeasureTime frameDescription
Clinical response3 weeks post treatmentMann Assessment of Swallowing Ability (M.A.S.A)and Functional Oral Intake Scale (F.O.I.S) change, without significant weight loss or dysphagia-related complication
Full clinical response3 months post treatmentMann Assessment of Swallowing Ability (M.A.S.A)and Functional Oral Intake Scale (F.O.I.S) change, without significant weight loss or dysphagia-related complication.

Secondary

MeasureTime frameDescription
Biomechanic evaluation of swallowing functionBaseline and 3 weeks (post treatment)Modified barium swallow measurement will be used to document changes in swallowing biomechanics associated with change in swallowing following treatment.
Functional stroke recoveryBaseline, 3 weeks (post treatment) and at 3-months post treatmentModified Rankin Scale and the Modified Barthel Index will be used to measure functional stroke recovery.
Recovery of pre-stroke dietBaseline, 3 weeks (post treatment) and 3 months postcomparison of diet intake
Patient perception of swallowing abilitybaseline, 3 weeks (post treatment) and at 3-months post treatmentUsing a visual analogue scale patients will indicate ability to swallow.
Neurological status/Stroke severitybaseline, 3 weeks (post treatment) and at the 3-month post treatmentNational Institutes of Health Stroke Scale will be used to measure neurological status change.
Dysphagia-related medical complicationsBaseline,3 weeks ( post treatment) and 3 months postOccurance of chest infection, dehydration or significant weight loss

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026